国际肿瘤学杂志››2015,Vol. 42››Issue (4): 281-283.doi:10.3760/cma.j.issn.1673-422X.2015.04.011
出版日期:
2015-04-08发布日期:
2015-04-22通讯作者:
郭延勋, Email:guo_21027@126.com
Online:
2015-04-08Published:
2015-04-22Contact:
Guo Yanxun, Email:guo_21027@126.com摘要:二甲双胍作为一种廉价安全高效的糖尿病药物已应用多年,近年来研究显示其对各种肿瘤细胞都有不同程度的抑制作用。二甲双胍的抗肿瘤机制尚未完全明确,可能与糖代谢及蛋白激酶途径有关,也可能与炎症因子介导肿瘤杀伤有关。二甲双胍对不同肿瘤细胞杀伤效果不同,对其他抗肿瘤治疗也有一些辅助作用。
郭延勋;马士崟. 二甲双胍的抗肿瘤作用[J]. 国际肿瘤学杂志, 2015, 42(4): 281-283.
GUO Yan-Xun-;Ma-Shi-Yin. Antitumor effects of metformin[J]. Journal of International Oncology, 2015, 42(4): 281-283.
[1] Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention[J]. Drug Saf, 2010, 33(9): 727740. [2] Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and metaanalysis[J]. Am J Epidemiol, 2014, 180(1): 1114. [3] Chen WW, Shao YY, Shau WY, et al. The impact of diabetes mellitus on prognosis of early breast cancer in Asia[J]. Oncologist, 2012, 17(4): 485491. [4] Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning[J]. Cancer Discov, 2012, 2(9): 778790. [5] Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro[J]. Cell Cycle, 2009, 8(6): 909915. [6] Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triplenegative breast cancers[J]. Cell Cycle, 2012, 11(2): 367376. [7] Menendez JA, OliverasFerraros C, Cufi S, et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells[J]. Cell Cycle, 2012, 11(15): 27822792. [8] Liu PP, Liao J, Tang ZJ, et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway[J]. Cell Death Differ, 2014, 21(1): 124135. [9] Singh S, Singh PP, Singh AG, et al. Antidiabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and metaanalysis[J]. Am J Gastroenterol, 2013, 108(4): 510519. [10] Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells[J]. Cancer Prev Res (Phila), 2012, 5(3): 355364. [11] Lonardo E, Cioffi M, Sancho P, et al. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells[J]. PLoS One, 2013, 8(10): e76518. [12] Gou S, Cui P, Li X, et al. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action[J]. PLoS One, 2013, 8(5): e63969. [13] Zhang T, Guo P, Zhang Y, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo[J]. Int J Mol Sci, 2013, 14(12): 2460324618. [14] Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patient with type 2 diabetes: a metaanalysis[J]. Diabetes Care, 2011, 34(10): 23232328. [15] Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a shortterm clinical trial[J]. Cancer Prev Res(Phila), 2010, 3(9): 10771083. [16] Coco C, Zannoni GF, Caredda E, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients[J]. J Exp Clin Cancer Res, 2012, 31(1): 7181. [17] Feng YH, Wu CL, Shiau AL, et al. MicroRNA21mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5fluorouracil and metformin in colon cancer cells[J]. Int J Mol Med, 2012, 29(5): 920926. [18] Saito T, Chiba T, Yuki K, et al. Metformin, a diabetes drug, eliminates tumorinitiating hepatocellular carcinoma cells[J]. PLoS One, 2013, 8(7): e70010. [19] Chen H, Liu X, Chen H, et al. Role of SIRT1 and AMPK in mesenchymal stem cells differentiation[J]. Ageing Res Rev, 2014, 13: 5564. [20] Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a preoperative, windowofopportunity, randomized trial[J]. Breast Cancer Res Treat, 2011, 128(3): 783794. [21] Lliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types[J]. Cancer Res, 2011, 71(9): 31963201. [22] Lliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types[J]. Cancer Res, 2011, 71(9): 31963201. [23] 张艳飞, 薛耀明, 江颖娟, 等. 二甲双胍联合5氟尿嘧啶抑制人结肠癌细胞SW620生长的实验研究[J]. 实用医学杂志, 2013, 29(17): 27842786. [24] Xu W, Lin H, Zhang Y, et al. Compound Kushen injection suppresses human breast cancer stemlike cells by downregulating the canonical Wnt/betacatenin pathway[J]. J Exp Clin Cancer Res, 2011, 30(1): 103108. [25] Takatani T, Minagawa M, Takatani R, et al. AMP activated protein kinase attenuates Wnt/βcatenin signaling in human osteoblastic Saos2 cells[J]. Mol Cell Endocrinol, 2011, 339(12): 114119. [26] Zhang T, Wang X, He D. Metformin sensitizes human bladder cancer cells to TRAILinduced apoptosis through mTOR/S6K1mediated downregulation of cFLIP[J]. Anticancer Drugs, 2014, 25(8): 887897. [27] Zannella VE, Dal PA, Muaddi H, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response[J]. Clin Cancer Res, 2013, 19(24): 67416750. [28] Li H, Chen X, Yu Y, et al. Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway[J]. Oncol Rep, 2014, 32(6): 25962604. [29] Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of nonsmall cell lung cancer (NSCLC) through ATM and AMPK[J]. Br J Cancer, 2013, 108(10): 20212032. [30] Bayraktar S, HernadezAya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptornegative breast cancer[J]. Cancer, 2012, 118(5): 12021211. |
[1] | 刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325. |
[2] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
[3] | 袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343. |
[4] | 陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349. |
[5] | 郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353. |
[6] | 张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. |
[7] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
[8] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
[9] | 张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375. |
[10] | 高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
[11] | 王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384. |
[12] | 刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273. |
[13] | 杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279. |
[14] | 王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285. |
[15] | 张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||